{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:39:39Z","timestamp":1791347979711,"version":"4.3.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["B2017\/BMD-3738"],"award-info":[{"award-number":["B2017\/BMD-3738"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Hospital Organization"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Awareness of racial\/ethnic disparities represents a key challenge for healthcare systems that attempt to provide effective healthcare and to reduce existing inequalities in the use of and adherence to guideline-recommended cardiovascular drugs to improve clinical outcomes for cardiovascular disease (CVD). In this review, we describe important racial\/ethnic differences between and within ethnic groups in the prevalence, risk factors, haemostatic factors, anti-inflammatory and endothelial markers, recurrence, and outcomes of CVD.<\/jats:p>\n                  <jats:p>We discuss important differences in the selection, doses, and response [efficacy and adverse drug reactions (ADRs)] in ethnically diverse patients treated with antithrombotics or lipid-lowering drugs. Differences in drug response are mainly related to racial\/ethnic differences in the frequency of polymorphisms in genes encoding drug-metabolizing enzymes (DMEs) and drug transporters. These polymorphisms markedly influence the pharmacokinetics, dose requirements, and safety of warfarin, clopidogrel, and statins. This review aims to support a better understanding of the genetic differences between and among populations to identify patients who may experience an ADR or a lack of drug response, thus optimizing therapy and improving outcomes. The greater the understanding of the differences in the genetic variants of DMEs and transporters that determine the differences in the exposure, efficacy, and safety of cardiovascular drugs between races\/ethnicities, the greater the probability that personalized medicine will become a reality.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvac040","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T09:24:06Z","timestamp":1658136246000},"page":"738-751","source":"Crossref","is-referenced-by-count":72,"title":["Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-7758","authenticated-orcid":false,"given":"Juan","family":"Tamargo","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Instituto De Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Universidad Complutense , 28040 Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Research Institute, St George's, University of London , London SW17 0RE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University , Kyoto 606-8303, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack Charles","family":"Barton","sequence":"additional","affiliation":[{"name":"Critical Care and Perioperative Medicine Research Group, Royal London Hospital , London \u00a0E1 1FR, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University , Kyoto 606-8303, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Division of Translational Research, National Hospital Organization Kyoto Medical Center , 1-1 Fukakusa Mukaihatacho, Kyoto 612-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-9756","authenticated-orcid":false,"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine & Intensive Care, Academic Teaching Hospital Bregenz, 6900 Bregenz, Austria; Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Academic Teaching Hospital Feldkirch, 6800 Feldkirch , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-6399","authenticated-orcid":false,"given":"Basil S","family":"Lewis","sequence":"additional","affiliation":[{"name":"Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology , Haifa 3200003 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-6312","authenticated-orcid":false,"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital , 0424 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-4043","authenticated-orcid":false,"given":"Koji","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Translational Research, National Hospital Organization Kyoto Medical Center , 1-1 Fukakusa Mukaihatacho, Kyoto 612-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"2022092908585130200_bib1","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"2022092908585130200_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/10601333.2015.1064131","article-title":"Inter-ethnic differences in drug response: implications for drug development and complying with drug regulation","volume":"32","author":"Shah","year":"2015","journal-title":"Clin Res Reg Affairs"},{"key":"2022092908585130200_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5551\/jat.RV16004","article-title":"Racial differences in the cholesterol-lowering effect of statin","volume":"24","author":"Naito","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"2022092908585130200_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvab018","article-title":"The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"8","author":"Magavern","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022092908585130200_bib5","first-page":"1204","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"2022092908585130200_bib6","first-page":"e9349","article-title":"Global epidemiology of ischemic heart disease: results from the Global Burden of Disease Study","volume":"12","author":"Khan","year":"2020","journal-title":"Cereus"},{"key":"2022092908585130200_bib7","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3390\/ijerph16071165","article-title":"Cardiovascular disease and the female disadvantage","volume":"16","author":"Woodward","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"2022092908585130200_bib8","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1161\/CIRCOUTCOMES.115.002621","article-title":"Sex and race\/ethnicity\u2014related disparities in care and outcomes after hospitalization for coronary artery disease among older adults","volume":"9","author":"Li","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022092908585130200_bib9","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1093\/eurheartj\/ehaa503","article-title":"An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation endorsed by Coronary Vasomotor Disorders International Study Group","volume":"41","author":"Kunadian","year":"2020","journal-title":"Eur Heart J"},{"key":"2022092908585130200_bib10","first-page":"914","article-title":"The 24-month prognosis of patients with positive or intermediate results in the intracoronary ergonovine provocation test","volume":"8","author":"Shin","year":"2015","journal-title":"JACC: Cardiovasc Interv"},{"key":"2022092908585130200_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2021.05.022","article-title":"Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: an ethnicity-based updated meta-analysis","volume":"90","author":"Jafrin","year":"2021","journal-title":"Eur J Internal Med"},{"key":"2022092908585130200_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/1060028018779082","article-title":"A review of ACE inhibitors and ARBs in black patients with hypertension","volume":"52","author":"Helmer","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2022092908585130200_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40885-019-0134-8","article-title":"Association between body mass index (BMI) and hypertension in south Asian population: evidence from nationally-representative surveys","volume":"25","author":"Hossain","year":"2019","journal-title":"Clin Hypertens"},{"key":"2022092908585130200_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/1573403X11666141122220003","article-title":"Disparities in cardiovascular disease risk in the United States","volume":"11","author":"Graham","year":"2015","journal-title":"Curr Cardiol Rev"},{"key":"2022092908585130200_bib15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","article-title":"JCS 2018 Guideline on diagnosis and treatment of acute coronary syndrome","volume":"83","author":"Kimura","year":"2019","journal-title":"Circ J"},{"key":"2022092908585130200_bib16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2022092908585130200_bib17","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022092908585130200_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2022092908585130200_bib19","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1253\/circj.CJ-20-1051","article-title":"Efficacy and safety of long-term evolocumab use among Asian subjects\u2014a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) Trial","volume":"85","author":"Keech","year":"2021","journal-title":"Circ J"},{"key":"2022092908585130200_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"2022092908585130200_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2022092908585130200_bib22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"2022092908585130200_bib23","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1055\/a-1346-3300","article-title":"Pharmacodynamic profile and prevalence of bleeding episode in East Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH Trial","volume":"121","author":"Jeong","year":"2021","journal-title":"Thromb Haemost"},{"key":"2022092908585130200_bib24","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jacc.2020.07.037","article-title":"Comparative trends in percutaneous coronary intervention in Japan and the United States, 2013 to 2017","volume":"76","author":"Inohara","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022092908585130200_bib25","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome\u2014randomized, double-blind, phase III PHILO study","volume":"79","author":"Goto","year":"2015","journal-title":"Circ J"},{"key":"2022092908585130200_bib26","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial","volume":"140","author":"Park","year":"2019","journal-title":"Circulation"},{"key":"2022092908585130200_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI Randomized Clinical Trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"2022092908585130200_bib28","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"2022092908585130200_bib29","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"2022092908585130200_bib30","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"2022092908585130200_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/jcm9030652","article-title":"Efficacy and safety of long-term and short-term dual antiplatelet therapy: a meta-analysis of comparison between Asians and non-Asians","volume":"9","author":"Ki","year":"2020","journal-title":"J Clin Med"},{"key":"2022092908585130200_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5853\/jos.2016.00052","article-title":"Asian patients with stroke plus atrial fibrillation and the dose of non-vitamin K oral anticoagulants","volume":"18","author":"Bang","year":"2016","journal-title":"J Stroke"},{"key":"2022092908585130200_bib33","article-title":"Outcomes after use of standard and low-dose non-vitamin K oral anticoagulants in Asian patients with atrial fibrillation","author":"Cho","journal-title":"Stroke"},{"key":"2022092908585130200_bib34","doi-asserted-by":"crossref","first-page":"e01417","DOI":"10.1161\/JAHA.119.014177","article-title":"Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation","volume":"9","author":"Yu","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2022092908585130200_bib35","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41598-020-58665-5","article-title":"Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"2022092908585130200_bib36","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.15420\/ecr.2020.24","article-title":"Anticoagulant therapy for patients with coronavirus disease 2019: urgent need for enhanced awareness","volume":"15","author":"Komiyama","year":"2020","journal-title":"Eur Cardiol Rev"},{"key":"2022092908585130200_bib37","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022092908585130200_bib38","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.14929","article-title":"Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"Spyropoulos","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2022092908585130200_bib39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/jama.2020.13372","article-title":"Thrombosis in hospitalized patients with COVID-19 in a New York city health system","volume":"324","author":"Bilaloglu","year":"2020","journal-title":"JAMA"},{"key":"2022092908585130200_bib40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5551\/jat.RPT001","article-title":"COVID-19-related thrombosis in Japan: final report of a questionnaire-based survey in 2020","volume":"28","author":"Horiuchi","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"2022092908585130200_bib41","doi-asserted-by":"crossref","first-page":"107602962110089","DOI":"10.1177\/10760296211008999","article-title":"Anticoagulation and in-hospital mortality from coronavirus disease 2019: a systematic review and meta-analysis","volume":"27","author":"Moonla","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"2022092908585130200_bib42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/0897190019894142","article-title":"Racial and ethnic differences in response to anticoagulation: a review of the literature","volume":"34","author":"Gibson","year":"2021","journal-title":"J Pharm Pract"},{"key":"2022092908585130200_bib43","article-title":"E17 general principles for planning and design of multi-regional clinical trials","author":"Guidande Document"},{"key":"2022092908585130200_bib44","first-page":"181","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC: Cardiovasc Interv"},{"key":"2022092908585130200_bib45","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO Trial","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022092908585130200_bib46","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ccd.27949","article-title":"CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: a meta-analysis of randomized clinical trials","volume":"93","author":"Kheiri","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2022092908585130200_bib47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI Randomized Clinical Trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"2022092908585130200_bib48","first-page":"1521","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC: Cardiovasc Interv"},{"key":"2022092908585130200_bib49","article-title":"National Institutes of Health Minority Health and Health Disparities Strategic Plan 2021\u20132025","year":"14  2022)"},{"key":"2022092908585130200_bib50","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1474515117741892","article-title":"Why is ethnicity important in cardiovascular care?","volume":"17","author":"Ski","year":"2018","journal-title":"Eur J Cardiovasc Nurs"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvac040\/45291825\/pvac040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/7\/738\/46168301\/pvac040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/7\/738\/46168301\/pvac040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T05:00:19Z","timestamp":1664427619000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/7\/738\/6644872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,15]]},"published-print":{"date-parts":[[2022,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvac040","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11]]},"published":{"date-parts":[[2022,7,15]]}}}